Talzenna
Recurrent Peripheral Primitive Neuroectodermal Tumor
St. Jude Children's Research HospitalPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
15 Active assets in the Recurrent Peripheral Primitive Neuroectodermal Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Palbociclib National Cancer Institute (NCI) | Phase 2 | B |
Tazemetostat National Cancer Institute (NCI) | Phase 2 | B |
PI3K/MTOR INHIBITOR LY3023414 National Cancer Institute (NCI) | Phase 2 | B |
VEMURAFENIB National Cancer Institute (NCI) | Phase 2 | CCC |
Selpercatinib National Cancer Institute (NCI) | Phase 2 | CCC |
View all 18 →
Same molecule, other indications
Talzenna is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →